Robert Hilbrands

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass

Bart Keymeulen, Melanie Walter, Chantal Mathieu et al. · Diabetologia · 2010 · 310 citations · Full text

Obesity, Metabolic Syndrome, Diabetes Management +12

Cellular Islet Autoimmunity Associates with Clinical Outcome of Islet Cell Transplantation

Volkert A.L. Huurman, Robert Hilbrands, Gabriëlle G.M. Pinkse et al. · PLoS ONE · 2008 · 192 citations · Full text

Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trial

Margaretha M. Visser, Sara Charleer, Steffen Fieuws et al. · The Lancet · 2021 · 158 citations · Full text

Type 1, Diabetes Management, Diabetes +7

Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial

Katherine R. Tuttle, Sibylle J. Hauske, María Eugênia Fernandes Canziani et al. · The Lancet · 2023 · 151 citations · Full text

Hypertension, Renal Function, Renal Disease +10

Differences in Baseline Lymphocyte Counts and Autoreactivity Are Associated With Differences in Outcome of Islet Cell Transplantation in Type 1 Diabetic Patients

Robert Hilbrands, Volkert A.L. Huurman, Pieter Gillard et al. · Diabetes · 2009 · 99 citations · Full text